Immunocore Holdings (IMCR) Stock Forecast & Price Target

Compare

199 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IMCR Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Immunocore

Holdings

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IMCR Stock 12 Month Forecast

Average Price Target

$67.50

▲(81.21%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Immunocore Holdings in the last 3 months. The average price target is $67.50 with a high forecast of $100.00 and a low forecast of $33.00. The average price target represents a 81.21% change from the last price of $37.25.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"$27","64":"$64","101":"$101","45.5":"$45.5","82.5":"$82.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$67.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,45.5,64,82.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.65,43.36923076923077,48.08846153846154,52.80769230769231,57.526923076923076,62.246153846153845,66.96538461538461,71.68461538461538,76.40384615384616,81.12307692307692,85.84230769230768,90.56153846153846,95.28076923076924,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.65,40.86923076923077,43.08846153846154,45.30769230769231,47.526923076923076,49.746153846153845,51.965384615384615,54.184615384615384,56.40384615384615,58.62307692307692,60.84230769230769,63.06153846153846,65.28076923076924,{"y":67.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.65,38.215384615384615,37.78076923076923,37.34615384615385,36.91153846153846,36.47692307692308,36.04230769230769,35.607692307692304,35.17307692307692,34.738461538461536,34.30384615384615,33.86923076923077,33.434615384615384,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.98,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.43,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.21,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$100.00

Average Price Target$67.50

Lowest Price Target$33.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$40

Hold

7.38%

Upside

Reiterated

06/06/25

Immunocore Holdings receives a moderate score due to strong revenue growth and improving cash flows, counterbalanced by persistent net losses and valuation concerns. Positive corporate events and bullish technical trends provide additional support, but overbought conditions warrant caution.

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$100

Buy

168.46%

Upside

Reiterated

06/03/25

Immunocore Holdings' Promising PRAME-Targeting Therapies Drive Buy Rating

James ShinDeutsche Bank

Deutsche Bank

$65

Buy

74.50%

Upside

Initiated

05/27/25

Immunocore Holdings (IMCR) Receives a New Rating from Deutsche Bank

Justin KimOppenheimer

Oppenheimer

$85→$86

Buy

130.87%

Upside

Reiterated

05/08/25

Immunocore price target raised to $86 from $85 at OppenheimerImmunocore price target raised to $86 from $85 at Oppenheimer

Tyler Van BurenTD Cowen

TD Cowen

$60

Buy

61.07%

Upside

Reiterated

05/07/25

Immunocore Holdings: Strong International Growth and Promising Clinical Trials Drive Buy Recommendation

Peter LawsonBarclays

Barclays

$66→$52

Buy

39.60%

Upside

Reiterated

05/07/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Geron (NASDAQ: GERN) and Immunocore Holdings (NASDAQ: IMCR)

Gil BlumNeedham

Needham

$71

Buy

90.60%

Upside

Reiterated

05/07/25

Immunocore Holdings: Strong Sales Growth and Financial Position Justify Buy Rating

Jonathan ChangLeerink Partners

Leerink Partners

$67

Buy

79.87%

Upside

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: BeiGene (NASDAQ: ONC), Immunocore Holdings (NASDAQ: IMCR) and Madrigal Pharmaceuticals (NASDAQ: MDGL)

Graig SuvannavejhMizuho Securities

Mizuho Securities

$33

Hold

-11.41%

Downside

Reiterated

05/07/25

Mizuho Securities Sticks to Its Hold Rating for Immunocore Holdings (IMCR)

Jessica FyeJ.P. Morgan

J.P. Morgan

$50

Buy

34.23%

Upside

Reiterated

04/11/25

J.P. Morgan Remains a Buy on Immunocore Holdings (IMCR)

Justin ZelinBTIG

BTIG

$91

Buy

144.30%

Upside

Reiterated

03/11/25

BTIG reiterates Buy Rating on Immunocore Holdings (IMCR), PT $91BTIG analyst Justin Zelin reiterated a Buy rating and $91.00 price target on Immunocore Holdings (NASDAQ: IMCR)

Sean LaamanMorgan Stanley

Morgan Stanley

$35

Hold

-6.04%

Downside

Initiated

03/07/25

Immunocore assumed with an Equal Weight at Morgan StanleyImmunocore assumed with an Equal Weight at Morgan Stanley

Rajan SharmaGoldman Sachs

Goldman Sachs

$75→$77

Buy

106.71%

Upside

Reiterated

02/28/25

Immunocore Holdings (IMCR) Receives a Buy from Goldman Sachs

Michael YeeJefferies

Jefferies

$55→$45

Buy

20.81%

Upside

Reiterated

12/19/24

Immunocore Holdings (IMCR) PT Lowered to $45 at JefferiesJefferies analyst Michael Yee lowered the price target on Immunocore Holdings (NASDAQ: IMCR) to $45.00 (from $55.00) while maintaining a Buy rating.

Jack AllenRobert W. Baird

Robert W. Baird

$84

Buy

125.50%

Upside

Reiterated

11/06/24

Immunocore Holdings: Strategic Advancements and Financial Stability Support Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$40

Hold

7.38%

Upside

Reiterated

06/06/25

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$100

Buy

168.46%

Upside

Reiterated

06/03/25

Immunocore Holdings' Promising PRAME-Targeting Therapies Drive Buy Rating

James ShinDeutsche Bank

Deutsche Bank

$65

Buy

74.50%

Upside

Initiated

05/27/25

Immunocore Holdings (IMCR) Receives a New Rating from Deutsche Bank

Justin KimOppenheimer

Oppenheimer

$85→$86

Buy

130.87%

Upside

Reiterated

05/08/25

Immunocore price target raised to $86 from $85 at OppenheimerImmunocore price target raised to $86 from $85 at Oppenheimer

Tyler Van BurenTD Cowen

TD Cowen

$60

Buy

61.07%

Upside

Reiterated

05/07/25

Immunocore Holdings: Strong International Growth and Promising Clinical Trials Drive Buy Recommendation

Peter LawsonBarclays

Barclays

$66→$52

Buy

39.60%

Upside

Reiterated

05/07/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Geron (NASDAQ: GERN) and Immunocore Holdings (NASDAQ: IMCR)

Gil BlumNeedham

Needham

$71

Buy

90.60%

Upside

Reiterated

05/07/25

Immunocore Holdings: Strong Sales Growth and Financial Position Justify Buy Rating

Jonathan ChangLeerink Partners

Leerink Partners

$67

Buy

79.87%

Upside

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: BeiGene (NASDAQ: ONC), Immunocore Holdings (NASDAQ: IMCR) and Madrigal Pharmaceuticals (NASDAQ: MDGL)

Graig SuvannavejhMizuho Securities

Mizuho Securities

$33

Hold

-11.41%

Downside

Reiterated

05/07/25

Mizuho Securities Sticks to Its Hold Rating for Immunocore Holdings (IMCR)

Jessica FyeJ.P. Morgan

J.P. Morgan

$50

Buy

34.23%

Upside

Reiterated

04/11/25

J.P. Morgan Remains a Buy on Immunocore Holdings (IMCR)

Justin ZelinBTIG

BTIG

$91

Buy

144.30%

Upside

Reiterated

03/11/25

BTIG reiterates Buy Rating on Immunocore Holdings (IMCR), PT $91BTIG analyst Justin Zelin reiterated a Buy rating and $91.00 price target on Immunocore Holdings (NASDAQ: IMCR)

Sean LaamanMorgan Stanley

Morgan Stanley

$35

Hold

-6.04%

Downside

Initiated

03/07/25

Immunocore assumed with an Equal Weight at Morgan StanleyImmunocore assumed with an Equal Weight at Morgan Stanley

Rajan SharmaGoldman Sachs

Goldman Sachs

$75→$77

Buy

106.71%

Upside

Reiterated

02/28/25

Immunocore Holdings (IMCR) Receives a Buy from Goldman Sachs

Michael YeeJefferies

Jefferies

$55→$45

Buy

20.81%

Upside

Reiterated

12/19/24

Jack AllenRobert W. Baird

Robert W. Baird

$84

Buy

125.50%

Upside

Reiterated

11/06/24

Immunocore Holdings: Strategic Advancements and Financial Stability Support Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunocore Holdings

1 Month

xxx

Success Rate

9/25 ratings generated profit

Average Return

-0.28%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 36.00% of your transactions generating a profit, with an average return of -0.28% per trade.

3 Months

xxx

Success Rate

14/25 ratings generated profit

Average Return

+8.58%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.00% of your transactions generating a profit, with an average return of +8.58% per trade.

1 Year

Jessica FyeJ.P. Morgan

Success Rate

8/13 ratings generated profit

Average Return

+13.77%

reiterated a buy rating 2 months ago

Copying Jessica Fye's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +13.77% per trade.

2 Years

xxx

Success Rate

7/13 ratings generated profit

Average Return

+7.75%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 53.85% of your transactions generating a profit, with an average return of +7.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMCR Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IMCR has received 10 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. IMCR average Analyst price target in the past 3 months is 67.50.

Each month's total comprises the sum of three months' worth of ratings.

IMCR Financial Forecast

IMCR Earnings Forecast

Next quarter’s earnings estimate for IMCR is -$0.20 with a range of -$0.59 to $0.11. The previous quarter’s EPS was $0.10. IMCR beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year IMCR has Outperformed its overall industry.

IMCR Sales Forecast

Next quarter’s sales forecast for IMCR is $91.84M with a range of $88.00M to $97.29M. The previous quarter’s sales results were $94.24M. IMCR beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year IMCR has Outperformed its overall industry.

IMCR Stock Forecast FAQ

What is IMCR’s average 12-month price target, according to analysts?

Based on analyst ratings, Immunocore Holdings Plc’s 12-month average price target is 67.50.

What is IMCR’s upside potential, based on the analysts’ average price target?

Immunocore Holdings Plc has 81.21% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IMCR a Buy, Sell or Hold?

Immunocore Holdings Plc has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Immunocore Holdings Plc’s price target?

The average price target for Immunocore Holdings Plc is 67.50. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $33.00. The average price target represents 81.21% Increase from the current price of $37.25.

What do analysts say about Immunocore Holdings Plc?

Immunocore Holdings Plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of IMCR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Immunocore Holdings (IMCR) Stock Forecast & Price Target

IMCR Analyst Ratings

IMCR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Immunocore Holdings

IMCR Analyst Recommendation Trends

IMCR Financial Forecast

IMCR Earnings Forecast

IMCR Sales Forecast

IMCR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts